Cutera Introduces Novel Laser Wavelength For Cosmetic Dermatology

Main Category: Dermatology
Also Included In: Cosmetic Medicine / Plastic Surgery;  Medical Devices / Diagnostics;  IT / Internet / E-mail
Article Date: 01 Feb 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

Cutera, Inc.(R) (Nasdaq: CUTR), a leading provider of laser and light-based aesthetic systems for practitioners worldwide, today announced it will preview a new laser technology at the 65th annual meeting of the American Academy of Dermatology (AAD), February 2-6, 2007. The proprietary YSGG technology generates a 2790 nm wavelength, which has specialized optical characteristics for minimally-invasive aesthetic procedures. This represents the first application of this wavelength in cosmetic dermatology.

"A growing number of patients and practitioners are interested in more pronounced improvement with moderate downtime in the treatment of fine lines, wrinkles and skin texture," said Kevin Connors, Cutera's CEO. "Our YSGG technology will allow us to participate in this emerging segment currently estimated at approximately $150 million and projected to be growing in excess of 30% per year."

The YSGG technology removes a portion of the epidermis with a controlled amount of thermal effect. Mr. Connors continued, "We expect collagen remodeling without the wound-healing trauma and significant discomfort associated with traditional ablative procedures. The thermal effect also creates a natural protective dressing on the skin to ensure moderate downtime."

The new YSGG technology complements Cutera's non-ablative, no-downtime aesthetic procedures. It will be available on Cutera's multi-application Xeo platform, as a standalone unit, and as an upgrade to all existing customers. Cutera filed a regulatory submission to the FDA in December 2006 and will begin formal marketing efforts once clearance has been granted by the Agency.

About Cutera, Inc.

Brisbane, Calif.-based Cutera is a leading provider of laser and other light-based aesthetic systems to the professional aesthetic market. Since 1998, Cutera has been developing innovative, easy-to-use products that enable dermatologists, plastic surgeons, gynecologists, primary care physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information visit http://www.cutera.com/.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the anticipated success of obtaining regulatory clearances, compiling effective clinical studies and making, marketing and selling new products are forward-looking statements within the meaning of the Safe Harbor. Forward-Looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Cutera's business and its financial results are detailed in its most recent 10-K and 10-Q as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Cutera, Inc.
http://www.cutera.com/

• Additional
• References
• Citations